Products Affected - Description
Mannitol injection, American Regent
250 mg/mL, 50 mL vial, 25 count (NDC 00517-4050-25)
Mannitol injection, Fresenius Kabi
250 mg/mL, 50 mL vial, 25 count (NDC 63323-0024-25)
Reason for the Shortage
American Regent has mannitol injection on shortage due to manufacturing delays.
Osmitrol injection, Baxter
50 mg/mL, 1000 mL premixed bag, 14 count (NDC 00338-0351-04)
200 mg/mL, 250 mL premixed bag, 36 count (NDC 00338-0357-02)
200 mg/mL, 500 mL premixed bag, 24 count (NDC 00338-0357-03)
Mannitol injection, BBraun
200 mg/mL, 250 mL premixed bag, 1 count (NDC 00264-7578-20)
200 mg/mL, 500 mL premixed bag, 1 count (NDC 00264-7578-10)
Mannitol injection, Hospira
200 mg/mL, 250 mL premixed bag, 24 count (NDC 00409-7715-02)
200 mg/mL, 500 mL premixed bag, 12 count (NDC 00409-7715-03)
250 mg/mL, 50 mL vial, 25 count (NDC 00409-4031-01)
Estimated Resupply Dates
- American Regent has mannitol 250 mg/mL 50 mL vials on back order and the company cannot estimate a release date.
- Fresenius Kabi has mannitol 250 mg/mL 50 mL vials on back order and the company estimates a release date of early-June 2016.
April 14, February 1, January 20 and 6, 2016; December 11, November 5, October 19 and 7, September 10, August 5, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins